Skip to main content
Top
Published in: Neurocritical Care 1/2022

01-02-2022 | Stroke | Original work

Causes, Predictors, and Timing of Early Neurological Deterioration and Symptomatic Intracranial Hemorrhage After Administration of IV tPA

Authors: Kavit Shah, Alexander Clark, Shashvat M. Desai, Ashutosh P. Jadhav

Published in: Neurocritical Care | Issue 1/2022

Login to get access

Abstract

Background

Acute ischemic stroke (AIS) is a major contributor toward healthcare-associated costs and services. Symptomatic intracranial hemorrhage (sICH) and early neurologic decline (END), defined as a National Health Institute Stroke Scale score decline of ≥ 4 within 24 h (with or without sICH), remain major concerns when administering intravenous tissue plasminogen activator (IV tPA) despite improved functional neurologic outcomes with its use. Given these risks, current guidelines recommend comprehensive stroke care (most often in an intensive care unit setting) for 24 h posttreatment. However, a number of patients may remain stable after IV tPA and thus not require such intensive resources. We sought to determine causes of END, along with timing and predictors of both sICH and END, to identify patients at lower risk of neurological deterioration and those suitable for earlier transition to a lower level of care.

Methods

This present study analyzed patients with AIS that presented within 4.5 h of being last seen well and received IV tPA. Baseline demographic, clinical, and radiographic findings were collected. Outcomes included END from any cause, parenchymal hemorrhage (PH1 or PH2), sICH, and mortality at 90 days.

Results

A total of 1238 patients with AIS without acute treatment of large vessel occlusion received IV tPA. 9.4% (116) had presence of any degree of ICH on noncontrast computed tomography head and 7.4% (91) experienced associated END. 2.7% (33) of patients experienced sICH, while 6.7% (83) experienced asymptomatic ICH. Of the patients with END, 63.7% did not have ICH. Predictive factors at presentation for END included an older age (72.6 ± 16.1 vs. 69.1 ± 14.8, p = 0.03), history of tobacco use (odds ratio [OR] 2.1 [1.1–4.3], p = 0.04), and hyperlipidemia (OR 1.7 [1.1–2.8], p = 0.02), along with the presence of an untreated large vessel occlusion (OR 2.1 [1.4–3.1], p = 0.02). Most END occurred within a mean time of 242 ± 251 min (4 ± 4 h). Because of the small proportion of patients suffering from sICH (33), predictors could not be determined; however, for patients with any ICH, predictive factors included an older age (74.6 ± 12.4 vs. 68.8 ± 15.1, p = 0.001), higher baseline National Health Institute Stroke Scale score (14.6 ± 7.3 vs. 10.8 ± 7.9, p = 0.002), and higher baseline glucose levels (155.1 ± 87.5 vs. 140.4 ± 70.5, p = 0.04).

Conclusions

In this study, only a small proportion suffered from either sICH and/or END, typically within 12 h of tPA administration. These findings may support earlier deescalation of higher acuity monitoring in clinically stable post-IV tPA patients without large vessel occlusion.
Literature
1.
go back to reference Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135:e146–603.CrossRef Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135:e146–603.CrossRef
2.
go back to reference GROUP TNIONDASr-PSS. Tissue Plasminogen Activator for Acute Ischemic Stroke. N Engl J Med 1995;333:1581–8. GROUP TNIONDASr-PSS. Tissue Plasminogen Activator for Acute Ischemic Stroke. N Engl J Med 1995;333:1581–8.
3.
go back to reference Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317–29.CrossRef Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317–29.CrossRef
4.
go back to reference Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017–25.CrossRef Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017–25.CrossRef
5.
go back to reference Adams HP, Adams RJ, Brott T, et al. Guidelines for the Early Management of Patients With Ischemic Stroke. Stroke. 2003;34:1056–83.CrossRef Adams HP, Adams RJ, Brott T, et al. Guidelines for the Early Management of Patients With Ischemic Stroke. Stroke. 2003;34:1056–83.CrossRef
6.
go back to reference Khan S, Soto A, Marsh EB. Resource Allocation: Stable Patients Remain Stable 12–24 h Post-tPA [published online ahead of print, 2019 Dec 9]. Neurocrit Care 2019. Khan S, Soto A, Marsh EB. Resource Allocation: Stable Patients Remain Stable 12–24 h Post-tPA [published online ahead of print, 2019 Dec 9]. Neurocrit Care 2019.
7.
go back to reference Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals From the American Heart Association/American Stroke Association. Stroke. 2019;50:e344–418.CrossRef Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals From the American Heart Association/American Stroke Association. Stroke. 2019;50:e344–418.CrossRef
8.
go back to reference Seners P, Turc G, Oppenheim C, Baron JC. Incidence, causes and predictors of neurological deterioration occurring within 24 h following acute ischaemic stroke: a systematic review with pathophysiological implications. J Neurol Neurosurg Psychiatry. 2015;86:87–94.CrossRef Seners P, Turc G, Oppenheim C, Baron JC. Incidence, causes and predictors of neurological deterioration occurring within 24 h following acute ischaemic stroke: a systematic review with pathophysiological implications. J Neurol Neurosurg Psychiatry. 2015;86:87–94.CrossRef
9.
go back to reference Grotta JC, Welch KM, Fagan SC, et al. Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial. Stroke. 2001;32:661–8.CrossRef Grotta JC, Welch KM, Fagan SC, et al. Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial. Stroke. 2001;32:661–8.CrossRef
10.
go back to reference Seners P, Turc G, Tisserand M, et al. Unexplained early neurological deterioration after intravenous thrombolysis: incidence, predictors, and associated factors. Stroke. 2014;45:2004–9.CrossRef Seners P, Turc G, Tisserand M, et al. Unexplained early neurological deterioration after intravenous thrombolysis: incidence, predictors, and associated factors. Stroke. 2014;45:2004–9.CrossRef
11.
go back to reference Simonsen CZ, Schmitz ML, Madsen MH, et al. Early neurological deterioration after thrombolysis: Clinical and imaging predictors. Int J Stroke. 2016;11:776–82.CrossRef Simonsen CZ, Schmitz ML, Madsen MH, et al. Early neurological deterioration after thrombolysis: Clinical and imaging predictors. Int J Stroke. 2016;11:776–82.CrossRef
12.
go back to reference Tisserand M, Seners P, Turc G, et al. Mechanisms of unexplained neurological deterioration after intravenous thrombolysis. Stroke. 2014;45:3527–34.CrossRef Tisserand M, Seners P, Turc G, et al. Mechanisms of unexplained neurological deterioration after intravenous thrombolysis. Stroke. 2014;45:3527–34.CrossRef
13.
go back to reference Yaghi S, Willey JZ, Cucchiara B, et al. Treatment and outcome of hemorrhagic transformation after intravenous alteplase in acute ischemic stroke: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2017;48:e343–61.PubMed Yaghi S, Willey JZ, Cucchiara B, et al. Treatment and outcome of hemorrhagic transformation after intravenous alteplase in acute ischemic stroke: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2017;48:e343–61.PubMed
14.
go back to reference Mori M, Naganuma M, Okada Y, et al. Early neurological deterioration within 24 hours after intravenous rt-PA therapy for stroke patients: the Stroke Acute Management with Urgent Risk Factor Assessment and Improvement rt-PA Registry. Cerebrovasc Dis. 2012;34:140–6.CrossRef Mori M, Naganuma M, Okada Y, et al. Early neurological deterioration within 24 hours after intravenous rt-PA therapy for stroke patients: the Stroke Acute Management with Urgent Risk Factor Assessment and Improvement rt-PA Registry. Cerebrovasc Dis. 2012;34:140–6.CrossRef
15.
go back to reference Tanaka K, Matsumoto S, Furuta K, et al. Differences between predictive factors for early neurological deterioration due to hemorrhagic and ischemic insults following intravenous recombinant tissue plasminogen activator. J Thromb Thrombolysis. 2020;49:545–50.CrossRef Tanaka K, Matsumoto S, Furuta K, et al. Differences between predictive factors for early neurological deterioration due to hemorrhagic and ischemic insults following intravenous recombinant tissue plasminogen activator. J Thromb Thrombolysis. 2020;49:545–50.CrossRef
16.
go back to reference Georgiadis D, Engelter S, Tettenborn B, et al. Early recurrent ischemic stroke in stroke patients undergoing intravenous thrombolysis. Circulation. 2006;114:237–41.CrossRef Georgiadis D, Engelter S, Tettenborn B, et al. Early recurrent ischemic stroke in stroke patients undergoing intravenous thrombolysis. Circulation. 2006;114:237–41.CrossRef
17.
go back to reference Group TNt-PSS. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 1997;28:2109–18. Group TNt-PSS. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 1997;28:2109–18.
18.
go back to reference Fernandez-Gotico H, Lightfoot T, Meighan M. Multicenter study of adverse events after intravenous tissue-type plasminogen activator treatment of acute ischemic stroke. J Neurosci Nurs. 2017;49:31–6.CrossRef Fernandez-Gotico H, Lightfoot T, Meighan M. Multicenter study of adverse events after intravenous tissue-type plasminogen activator treatment of acute ischemic stroke. J Neurosci Nurs. 2017;49:31–6.CrossRef
19.
go back to reference Larrue V, von Kummer RR, Müller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke. 2001;32:438–41.CrossRef Larrue V, von Kummer RR, Müller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke. 2001;32:438–41.CrossRef
20.
go back to reference Tsivgoulis G, Zand R, Katsanos AH, et al. Risk of symptomatic intracerebral hemorrhage after intravenous thrombolysis in patients with acute ischemic stroke and high cerebral microbleed burden: a meta-analysis. JAMA Neurol. 2016;73:675–83.CrossRef Tsivgoulis G, Zand R, Katsanos AH, et al. Risk of symptomatic intracerebral hemorrhage after intravenous thrombolysis in patients with acute ischemic stroke and high cerebral microbleed burden: a meta-analysis. JAMA Neurol. 2016;73:675–83.CrossRef
21.
go back to reference Nisar T, Hanumanthu R, Khandelwal P. Symptomatic intracerebral hemorrhage after intravenous thrombolysis: predictive factors and validation of prediction models. J Stroke Cerebrovasc Dis. 2019;28:104360.CrossRef Nisar T, Hanumanthu R, Khandelwal P. Symptomatic intracerebral hemorrhage after intravenous thrombolysis: predictive factors and validation of prediction models. J Stroke Cerebrovasc Dis. 2019;28:104360.CrossRef
22.
go back to reference Faigle R, Butler J, Carhuapoma JR, et al. Safety trial of low-intensity monitoring after thrombolysis: optimal post Tpa-Iv monitoring in ischemic STroke (OPTIMIST). The Neurohospitalist. 2020;10:11–5.CrossRef Faigle R, Butler J, Carhuapoma JR, et al. Safety trial of low-intensity monitoring after thrombolysis: optimal post Tpa-Iv monitoring in ischemic STroke (OPTIMIST). The Neurohospitalist. 2020;10:11–5.CrossRef
Metadata
Title
Causes, Predictors, and Timing of Early Neurological Deterioration and Symptomatic Intracranial Hemorrhage After Administration of IV tPA
Authors
Kavit Shah
Alexander Clark
Shashvat M. Desai
Ashutosh P. Jadhav
Publication date
01-02-2022
Publisher
Springer US
Keyword
Stroke
Published in
Neurocritical Care / Issue 1/2022
Print ISSN: 1541-6933
Electronic ISSN: 1556-0961
DOI
https://doi.org/10.1007/s12028-021-01266-5

Other articles of this Issue 1/2022

Neurocritical Care 1/2022 Go to the issue